We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-0.31%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$6.88B
AUM Growth
-$822M
Cap. Flow
-$1.07B
Cap. Flow %
-15.57%
Top 10 Hldgs %
44.23%
Holding
173
New
23
Increased
20
Reduced
28
Closed
33

Top Buys

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$65.2M
2
PRCT icon
Procept Biorobotics
PRCT
+$63.6M
3
FOLD
Amicus Therapeutics
FOLD
+$35.2M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$32.5M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$31.4M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$93.6M
2
NVRO
NEVRO CORP.
NVRO
+$73.1M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$60.8M
4
MDT icon
Medtronic
MDT
+$55.9M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.92%
2 Financials 0.85%
3 Industrials 0.17%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCXI
101
DELISTED
ChemoCentryx, Inc.
CCXI
$9.4M 0.14%
+550,000
New +$8.57M
PMVP icon
102
PMV Pharmaceuticals
PMVP
$57.1M
$8.99M 0.13%
301,714
-444,843
-60% -$14.2M
SGHT icon
103
Sight Sciences
SGHT
$291M
$8.85M 0.13%
+390,000
New +$12.8M
FULC icon
104
Fulcrum Therapeutics
FULC
$241M
$8.3M 0.12%
294,118
– –
PRTA icon
105
Prothena Corp
PRTA
$448M
$7.12M 0.1%
100,000
– –
CNCE
106
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$7.03M 0.1%
2,150,641
– –
RPID icon
107
Rapid Micro Biosystems
RPID
$102M
$6.46M 0.09%
+350,000
New +$7.23M
FLNA
108
PUT
Filana Therapeutics
FLNA
$42M
$6.21M 0.09%
+100,000
New +$8.35M
NEPT
109
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$6.08M 0.09%
7,183
-1,995
-22% -$2.11M
PRVB
110
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$6.07M 0.09%
948,481
– –
TSHA icon
111
Taysha Gene Therapies
TSHA
$1.61B
$5.97M 0.09%
320,440
– –
ACHL
112
DELISTED
Achilles Therapeutics
ACHL
$5.88M 0.09%
755,375
– –
PSTX
113
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$5.74M 0.08%
787,745
– –
ATEC icon
114
Alphatec Holdings
ATEC
$1.48B
$5.25M 0.08%
430,900
-1,369,280
-76% -$19.1M
DALS
115
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$4.92M 0.07%
+500,000
New +$4.94M
TBIO
116
DELISTED
Telesis Bio, Inc. Common Stock
TBIO
$4.73M 0.07%
23,611
– –
DRIO icon
117
DarioHealth
DRIO
$51.9M
$4.47M 0.07%
16,393
– –
OBIO icon
118
Orchestra BioMed
OBIO
$228M
$4.45M 0.06%
450,000
– –
RGNX icon
119
Regenxbio
RGNX
$616M
$3.74M 0.05%
89,283
– –
SRZN icon
120
Surrozen
SRZN
$223M
$3.54M 0.05%
+33,333
New +$4.69M
VYNE icon
121
VYNE Therapeutics
VYNE
$3.24M 0.05%
2,589
-3,827
-60% -$7.42M
SNCE
122
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.94M 0.04%
15,000
– –
TARA icon
123
Protara Therapeutics
TARA
$214M
$2.92M 0.04%
421,641
– –
AXSM icon
124
Axsome Therapeutics
AXSM
$11.7B
$2.65M 0.04%
80,420
-473,488
-85% -$18.5M
IMGO
125
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$2.5M 0.04%
+125,000
New +$2.68M
3 4
5
6 7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Perceptive Advisors held 173 positions worth $6.88B, down 11% from $7.71B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $1.07B in Q3 2021, closing 33 positions and reducing 28 holdings. Its most notable exit was Kadmon Holdings, Inc., an estimated $60.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in Icosavax, Inc. Common Stock worth $56.9M.

  • Perceptive Advisors's largest Q3 2021 buy was Icosavax, Inc. Common Stock: 1,922,549 shares worth $56.9M.
  • Perceptive Advisors added most to Amicus Therapeutics in Q3 2021, an estimated $35.2M increase.
  • Perceptive Advisors's biggest Q3 2021 reduction was United Therapeutics, cutting an estimated $93.6M.
  • Perceptive Advisors fully exited Kadmon Holdings, Inc. in Q3 2021, selling an estimated $60.8M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $6.88B portfolio in Q3 2021.
  • Perceptive Advisors opened 23 new positions and closed 33 in Q3 2021.
  • Perceptive Advisors's portfolio value fell 11% quarter-over-quarter to $6.88B.

Based on Perceptive Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.